Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Early outcomes associated with de novo once‐daily extended‐release versus twice‐daily immediate‐release tacrolimus in a predominantly African American kidney transplant population: A single‐center observational study2024
2. 2#2084 Biologic effect evaluation of de novo long-term release tacrolimus on metabolizer phenotype and T cell composition after kidney transplantation2024
3. 3A Five‐Year Prospective, Randomized, Open‐Label Study of Standard‐Dose Versus Low‐Dose Prolonged‐Release Tacrolimus With or Without Angiotensin‐Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation2024
4. 4Age-related differences in rejection rates, infections and tacrolimus exposure in pediatric kidney transplant recipients – a benchmark study of the CERTAIN registry2024
5. 5Plasma versus Whole Blood Tacrolimus Concentration and Outcomes After Kidney Transplantation2026